- Home
- DTSS vs NLSP Comparison
DTSS vs NLSP Comparison
Compare DTSS & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- NLSP
- Stock Information
- Founded
- DTSS 2014
- NLSP 2015
- Country
- DTSS China
- NLSP Switzerland
- Employees
- DTSS N/A
- NLSP N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- DTSS Technology
- NLSP Health Care
- Exchange
- DTSS Nasdaq
- NLSP Nasdaq
- Market Cap
- DTSS 10.3M
- NLSP 243.8M
- IPO Year
- DTSS N/A
- NLSP 2021
- Fundamental
- Price
- DTSS $2.38
- NLSP $4.55
- Analyst Decision
- DTSS
- NLSP
- Analyst Count
- DTSS 0
- NLSP 0
- Target Price
- DTSS N/A
- NLSP N/A
- AVG Volume (30 Days)
- DTSS 941.0K
- NLSP 33.1K
- Earning Date
- DTSS 11-11-2024
- NLSP 11-01-2024
- Dividend Yield
- DTSS N/A
- NLSP N/A
- EPS Growth
- DTSS N/A
- NLSP N/A
- EPS
- DTSS N/A
- NLSP N/A
- Revenue
- DTSS $23,975,867.00
- NLSP N/A
- Revenue This Year
- DTSS N/A
- NLSP N/A
- Revenue Next Year
- DTSS N/A
- NLSP N/A
- P/E Ratio
- DTSS N/A
- NLSP N/A
- Revenue Growth
- DTSS 558.55
- NLSP N/A
- 52 Week Low
- DTSS $1.42
- NLSP $4.08
- 52 Week High
- DTSS $20.29
- NLSP $29.84
- Technical
- Relative Strength Index (RSI)
- DTSS 54.30
- NLSP 40.59
- Support Level
- DTSS $2.10
- NLSP $4.38
- Resistance Level
- DTSS $2.49
- NLSP $5.64
- Average True Range (ATR)
- DTSS 0.23
- NLSP 0.47
- MACD
- DTSS 0.00
- NLSP 0.06
- Stochastic Oscillator
- DTSS 40.00
- NLSP 29.16
About DTSS Datasea Inc.
Datasea Inc is a development stage company engaged in Internet security products. Its offers service and products such as Internet Security Equipment, New Media Advertising Service, Micro Marketing Service, Internet Service Provider (ISP) Connecting Service, Big Data Processing Service. The business activity of the group functions through China.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.